Introduction
============

Breast carcinoma is the most common malignant tumor and leading cause of cancer mortality in women worldwide ([@b1-ol-0-0-11297]). Breast tissue biopsies remain the best way to diagnose breast carcinoma. When malignant breast lumps are localized to the breast tissue, the relative cure rate of radical mastectomy or radiotherapy and chemotherapy is high. However, if breast carcinoma is detected at an advanced stage, and the carcinoma cells have spread outside the breast tissue, the prognosis for survival is substantially decreased ([@b2-ol-0-0-11297]). Although the precise molecular mechanism of breast carcinoma progression remains unclear, numerous studies have revealed that transforming growth factor-β (TGF-β)/SMAD family member (Smad) signaling pathways that regulate cell growth, differentiation, proliferation and apoptosis serve an important function in the progression of breast carcinoma ([@b3-ol-0-0-11297]--[@b5-ol-0-0-11297]).

The TGF-β signaling pathway is activated when TGF-β directly binds to transmembrane TGF-β type II receptors (TβRIIs); subsequently, TβRII recruits and activates TβRI. In turn, Smad2 or Smad3 transiently bind to TβRI and become activated by TβRI-induced phosphorylation in the cytoplasm. Phosphorylated (p-)Smad2 or p-Smad3 form a heterologous complex with a co-Smad (Smad4), which is translocated from the cytoplasm into the nucleus and binds to specific DNA sequences to regulate particular gene transcription ([@b6-ol-0-0-11297]).

Activated Smad2 or Smad3 exert different effects on the biological function of carcinoma cells ([@b7-ol-0-0-11297]). In gastric carcinoma, Smad2 is considered to protect the gastric mucosal epithelium from malignant transformation, whereas Smad3 is not directly associated with the initiation of gastric carcinoma, but is associated with the epithelial-mesenchymal transition (EMT) in gastric epithelial cells ([@b8-ol-0-0-11297]). In MDA-MB-231 breast carcinoma cells, Smad2 and Smad3 have diametrically opposite effects, with Smad3 knockdown resulting in a delayed bone metastasis of carcinoma cells, and Smad2 knockdown resulting in an enhanced invasive ability of MDA-MB-231 cells ([@b9-ol-0-0-11297]).

Smad4 has been identified as a tumor suppressor gene, and its mutation inactivation or decreased expression is often observed in tumor tissues, including colorectal and pancreatic carcinomas ([@b10-ol-0-0-11297],[@b11-ol-0-0-11297]). So far, information regarding the function of Smad4 in breast carcinoma is very limited. A previous study revealed that the expression of Smad4 in breast carcinoma tissue was lower compared with that of surrounding normal adjacent breast epithelial tissue, but the survival time of patients who were Smad4-negative was longer ([@b12-ol-0-0-11297]). In addition, certain scholars believe that Smad4 may inhibit the growth of breast carcinoma cells by inducing apoptosis ([@b13-ol-0-0-11297]). However, subsequent to studying the MCF10 cell series, corresponding to different stages of breast cancer progression, it was revealed that the expression level of the Smad4 protein increased from non-malignant to highly malignant in highly invasive cells ([@b14-ol-0-0-11297]). Above all else, the aforementioned studies indicate that the function of Smad4 protein in the progression of breast carcinoma is very complex.

In the present study, the ductal carcinoma subtype with the highest incidence in breast cancer was selected as the subject of the study ([@b15-ol-0-0-11297]). Immunohistochemistry was used to examine the expression of Smad2, p-Smad2 and Smad4 in 126 invasive breast ductal carcinoma tissues, in order to investigate the correlation between the expression of these proteins and various clinicopathological parameters, in addition to the consistency of expression among them, analyze combined markers and identify prognostic factors for patients with breast ductal carcinoma.

Materials and methods
=====================

### Patients and tissue specimens

A total of 126 breast ductal carcinoma specimens were collected from the Department of General Surgery of Beihua University Affiliated Hospital (Jilin, China) between January 2009 and December 2010. All specimens were confirmed by hematoxylin-eosin staining for invasive breast ductal carcinoma. No preoperative radiotherapy, chemotherapy or other antitumor treatments were available. All patients were female, aged 28--84 years (median age, 48 years). Out of all cases, 17 were well-differentiated, 79 moderately differentiated and 30 poorly differentiated. All patients were followed up until December 2014. The overall survival (OS) time was defined as the time between initial surgery and mortality or last follow-up. The OS time was 8.5--69.5 months, and the median survival time 49 months. The progression-free survival (PFS) time was defined as the time between initial surgery and deterioration (relapse or metastasis) or mortality. The PFS time was 5--69.5 months, and the median progression time 34.5 months.

A portion of the samples were fixed in 10% buffered formalin at 37°C for 3 h and embedded in paraffin. Specimens were stained with hematoxylin for 5 min and eosin for 20--30 sec at room temperature and examined histopathologically. Clinicopathological parameters, including age, tumor size, lymph node metastasis, distant metastasis, histological grade, estrogen (ER), progesterone (PR) and human epidermal growth factor receptor 2 (HER2) were available for all patients.

### Immunohistochemical assay

Immunohistochemical assays were performed using the conventional streptavidin-peroxidase method. In brief, 5 µm thick paraffin-embedded tissues were dewaxed using xylene and dehydrated using ethanol gradient (100, 95 and 80%). Antigen retrieval buffer (citric acid and sodium citrate preparation) was used for incubating tissue sections. Sections were boiled (95°C) for 20 min and then cooled until they reached room temperature. Endogenous peroxidase was blocked using 3% hydrogen peroxide (Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) for 10 min at 37°C. To eliminate non-specific staining, the sections were incubated with goat serum (Fuzhou Maixin Biotech Co., Ltd.) for 20 min at room temperature. They were then incubated with rabbit polyclonal anti-Smad2 (cat. no. ab63576; Abcam, Cambridge, UK), rabbit polyclonal anti-Smad2 (phospho S467; cat. no. ab53100; Abcam) and rabbit monoclonal anti-Smad4 (cat. no. ab40759; Abcam) antibodies at 4°C overnight. These antibodies were diluted at a ratio of 1:100. Following 3 washes in PBS, biotinylated anti-rabbit immunoglobulin (cat. no. KIT-9707; Fuzhou Maixin Biotech Co., Ltd.) were applied for 10 min at room temperature. Processing was then conducted in a humidified chamber at room temperature by the addition of streptavidin-peroxidase (cat. no. KIT-9707; Fuzhou Maixin Biotech Co., Ltd.) for 10 min. Next, the specimens were washed in PBS and color-developed with 3,3′-diaminobenzidine (Fuzhou Maixin Biotech Co., Ltd.) and hydrogen peroxide for 5 min. Subsequently, they were counterstained with Mayer\'s hematoxylin (Fuzhou Maixin Biotech Co., Ltd.) for 30 sec-1 min at room temperature. Negative controls were obtained by omission of the primary antibody and substitution of the primary antibody with normal serum. The positive control comprised a section of a breast ductal carcinoma block previously demonstrated to be positive for the marker, which was incorporated in each run. Stained specimens were imaged under a light microscope (magnifications ×200 and ×400).

### Immunohistochemistry evaluation

All immunohistochemistry-stained sections were scored by at least 3 of the 4 independent experienced pathologists involved in the present study (Dr Nannan Liu, Dr Chunyan Yu, Dr Dongxue Qi and Dr Jihong Zhang) who had no prior knowledge of the clinicopathologic parameters and clinical outcomes of the patients. The distribution and intensity of Smad2, p-Smad2 and Smad4 staining were observed using light microscopy (CX31; Olympus Corporation, Tokyo, Japan), and at least 5 fields (×400) were analyzed for each tissue section. Staining was evaluated using the Taubert scoring system as previously described ([@b16-ol-0-0-11297]), according to the proportion of stained cells and staining intensity. The number of immunopositive cells was semi-quantitatively estimated as follows: i) The percentage of positive cells was scored as 1 (1--10%), 2 (11--50%), 3 (51--75%) and 4 (\>75%); ii) Staining intensity was scored as 0 (absent), 1 (weak), 2 (moderate) and 3 (intense). The immunoreactive scores (IRS) were calculated by multiplying the scores of i) and ii) ([@b17-ol-0-0-11297]), and were as follows: 0, no staining; 1--4, weak staining; 5--8, moderate staining; and 9--12, strong staining. An IRS of \<1 was considered to indicate a negative staining score for p-Smad2 and Smad4. The median score (6.3) was selected as the cutoff point for the separation of 'high Smad2 expression' (score \> median) from 'low Smad2 expression' (score ≤ median) tissue sections. Results were confirmed by a repeat of the staining experiment on sequential sections from the same block.

### Statistical analysis

Statistical analysis was conducted using SPSS software version 25 for Windows (IBM Corp., Armonk, NY, USA). The data were presented as the means of IRS values calculated for each section. The Spearman\'s rank correlations coefficient was calculated for analyzing the correlation between the expression of Smad2, p-Smad2 and Smad4 and various clinicopathological parameters. Cohen\'s κ coefficient was used to evaluate inter-observer consistency in the quantification. The Kaplan-Meier method (log-rank test) was used for OS and PFS curves. Cox regression was used for univariate and multivariate analysis for OS and PFS. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Association between Smad2, p-Smad2 and Smad4 expression and clinicopathological parameters

Immunohistochemistry was performed to determine the expression of Smad2, p-Smad2 and Smad4 in 126 primary breast ductal carcinoma tissue specimens. As expected, immunohistochemistry staining exhibited a predominantly cytoplasmic pattern of the Smad4 protein expression, while Smad2 and p-Smad2 were revealed in the cytoplasm and nuclear compartments ([Fig. 1](#f1-ol-0-0-11297){ref-type="fig"}). According to the IRS criteria, no cases of Smad2-negative expression were observed among the evaluated specimens. The median score of all cases was 5.7, with 60 (47.6%) carcinoma tissues being Smad2-low (IRS\<5.7) and 66 (52.4%) being Smad2-high (IRS≥5.7). However, p-Smad2 and Smad4 were negatively expressed in a proportion of cells. A total of 25 (19.8%) carcinoma tissues were p-Smad2-negative (IRS\<1), while 101 (80.2%) stained positive (1≤IRS≤12). In addition, 21 (16.7%) carcinoma tissues were Smad4-negative (IRS\<1) and 105 (83.3%) stained positive (1≤IRS≤12).

The association between the expression of Smad2, p-Smad2 and Smad4 and clinicopathological parameters was further analyzed. Significant correlations were identified between Smad4 and HER2 expression (r=−0.179, P=0.044; [Table I](#tI-ol-0-0-11297){ref-type="table"}), but there was no statistically significant correlation between Smad4 expression and any other clinicopathological parameters, including age, tumor size, lymph node metastasis, distant metastasis, histological grade, ER and PR (P\>0.05; [Table I](#tI-ol-0-0-11297){ref-type="table"}). Furthermore, no statistically significant correlation was discovered between the expression of p-Smad2 and Smad2 and any of the various clinicopathological parameters (P\>0.05; [Table I](#tI-ol-0-0-11297){ref-type="table"}).

### Consistent association among Smad4, p-Smad2 and Smad2 expression

A p-Smad2/Smad4 co-positive expression was observed in 100/126 cases. A p-Smad2/Smad4 co-negative expression was observed in 20/126 cases. In addition, 5/126 cases had a p-Smad2(−)/Smad4(+) and 1 had a p-Smad2(+)/Smad4(−) expression. Of note, according to the κ consistency test results, a significant agreement in the classification for Smad4 and p-Smad2 was revealed in all tissue specimens (κ=0.841, P\<0.001; [Table II](#tII-ol-0-0-11297){ref-type="table"}). However, the consistent association was not presented in classification for between Smad2 and p-Smad2 (κ=0.024, P=0.394; data not shown) or Smad2 and Smad4 (κ=−0.013, P=0.632; data not shown).

### Association between Smad2, p-Smad2 and Smad4 expression and the survival of patients with breast ductal carcinoma

Kaplan-Meier analysis revealed that patients with an Smad4-negative expression were likely to have a significantly shorter OS time (P=0.046; [Fig. 2](#f2-ol-0-0-11297){ref-type="fig"}) and PFS time (P=0.034; [Fig. 2](#f2-ol-0-0-11297){ref-type="fig"}) in all 126 specimens compared with Smad4-positive patients. However, no significant difference in OS time (P=0.181; data not shown) or PFS time (P=0.063; data not shown) was detected between patients with a positive and negative p-Smad2 expression. In addition, no significant difference was identified in OS time (P=0.617; data not shown) or PFS time (P=0.552; data not shown) between patients with a positive and negative Smad2 expression.

### Univariate and multivariate analysis of prognostic variables in 126 patients with breast ductal carcinoma

Univariate analysis revealed that distant metastasis significantly predicted an increased risk of breast carcinoma progression (P=0.017; [Table III](#tIII-ol-0-0-11297){ref-type="table"}) and poor OS time (P=0.010; [Table III](#tIII-ol-0-0-11297){ref-type="table"}). However, the risk of breast carcinoma progression was significantly decreased in patients with Smad4-positive expression (P=0.040; [Table III](#tIII-ol-0-0-11297){ref-type="table"}), an effect that was not observed for OS time (P=0.051; [Table III](#tIII-ol-0-0-11297){ref-type="table"}). Other clinicopathological parameters did not exhibit any statistically significant difference in prognostic risk assessment (P\>0.05; [Table III](#tIII-ol-0-0-11297){ref-type="table"}). Multivariate Cox analysis revealed that Smad4 expression did not remain a statistically significant marker of deterioration \[hazard ratio (HR), 0.539; 95% confidence interval (CI), 0.290--1.002; P=0.051; data not shown\] once distant metastasis had been taken into account, whereas distant metastasis remained a significant independent predictor (HR, 2.945; 95% CI, 1.257--6.902; P=0.013; data not shown).

### Association between co-negative and co-positive p-Smad2/Smad4 expression and the survival of patients with breast ductal carcinoma

Since Smad4 expression was significantly consistent with p-Smad2 expression, as confirmed by Cohen\'s κ coefficient, patients were divided into two subgroups, according to their co-negative or co-positive p-Smad2/Smad4 expression. As revealed by Kaplan-Meier analysis, patients in the p-Smad2/Smad4 co-negative expression subgroups had a significantly shorter OS time (P=0.042; [Fig. 3](#f3-ol-0-0-11297){ref-type="fig"}) and PFS time (P=0.019; [Fig. 3](#f3-ol-0-0-11297){ref-type="fig"}) compared with those in the co-positive expression subgroups.

### Univariate and multivariate analysis of prognostic variables in patients with breast ductal carcinoma with a co-negative and co-positive p-Smad2/Smad4 expression

Univariate analysis results indicated that distant metastasis and p-Smad2/Smad4 co-expression were significantly associated with OS time (P=0.022 and P=0.047, respectively; [Table IV](#tIV-ol-0-0-11297){ref-type="table"}) and PFS time (P=0.012 and P=0.023, respectively; [Table IV](#tIV-ol-0-0-11297){ref-type="table"}). Nevertheless, the other clinicopathological parameters evaluated, including age, tumor size, lymph node metastasis, histological type, ER, PR and HER2 expression did not significantly affect OS and PFS time ([Table IV](#tIV-ol-0-0-11297){ref-type="table"}). Furthermore, multivariate Cox regression analysis indicated that distant metastasis and co-negative or co-positive p-Smad2/Smad4 expression were also independent predictors for OS time (P=0.024 and P=0.049, respectively; [Table V](#tV-ol-0-0-11297){ref-type="table"}) and PFS time (P=0.017 and P=0.030, respectively; [Table V](#tV-ol-0-0-11297){ref-type="table"}) of patients with breast ductal carcinoma.

Discussion
==========

The results of the present study revealed that the Smad4 expression was significantly negatively correlated with the expression of HER2 in breast carcinoma tissues; as the positive rate of Smad4 expression gradually decreased, the positive expression rate of HER2 increased correspondingly, suggesting that the expression characteristics of Smad4(−)/HER2(+) were present in a portion of breast ductal carcinomas specimens. Although no direct correlation has been reported between Smad4 and HER2, it has been reported that the TGF-β/Smad and the HER2/Ras/extracellular signal-regulated kinase (Erk) mitogen-activated protein kinase (MAPK) pathway often directly interact and mutually regulate the activities or expression of each other ([@b18-ol-0-0-11297]). One function of elevated HER2 activity in breast carcinoma is to impede the growth inhibitory function of TGF-β via the phosphorylation of R-Smad proteins by Erk MAPK ([@b19-ol-0-0-11297]). It means that HER2-mediated signal transformation may involve the shutdown of the TGF-β/Smad tumor suppressive pathway. Subsequently, the inactivation of Smad4 may further interfere with TGF-β-induced growth inhibition. Similarly, in human pancreatic ductal adenocarcinoma, the activation of HER2 and inactivation of Smad4 were also the most frequent gene alterations, which enabled human pancreatic ductal epithelial cells to acquire sustaining proliferative signaling, evade growth suppressors and finally result in tumorigenic transformation ([@b20-ol-0-0-11297]). This may not explain why patients with an Smad4-negative expression were more likely to be HER2-positive in breast ductal carcinoma tissues, but it may be important for understanding the expression characteristics of Smad4(−)/HER2(+) in certain breast carcinoma specimens. In addition, the study revealed that patients with breast carcinoma with a high HER2 expression were generally associated with a poor prognosis and high carcinoma cell proliferation ([@b21-ol-0-0-11297]), suggesting that HER2 has a positive regulatory effect on the proliferation of cancer cells. By contrast, Smad4 functions as a tumor-suppressor gene, which results in a negative regulatory effect on the proliferation of cancer cells ([@b22-ol-0-0-11297]). Therefore, there is expected to be a negative correlation between the expression of Smad4 and HER2 in breast carcinoma tissues, but the detailed underlying molecular mechanism and co-regulation signal loop need to be further studied.

Although Smad2 is not so much regarded as a tumor-suppressor gene, certain studies have demonstrated that the functional inactivation of Smad2 is sufficient to inhibit the physiological function of TGF-β ([@b23-ol-0-0-11297],[@b24-ol-0-0-11297]). Furthermore, one previous study tested Smad2-targeted knockout mouse keratinocytes and revealed that Smad2^−/−^ mice did not naturally develop into skin tumor types, but that Smad2 may accelerate tumor formation and malignant transformation in chemical carcinogenesis experiments, and that Smad2^−/−^ skin cancer was poorly differentiated and exhibited an increase in EMT, indicating that an Smad2-deficient epithelium was more likely to form a tumor and malignant transformation ([@b25-ol-0-0-11297]). Accordingly, Smad2-deficiency in mice did not cause intestinal tumor types, but it may accelerate the malignant progression of late-stage invasive tumor types ([@b26-ol-0-0-11297]). In the present study, Smad2 was not negatively expressed in any of the 126 breast ductal carcinoma tissues, but 25 tissues were p-Smad2-negative. It was clear that these 25 specimens were due to a lack of phosphorylation, not due to a loss of Smad2 expression. More importantly, of the p-Smad2-negative cases, 20 exhibited a p-Smad2/Smad4 co-negative expression. Previous studies have revealed that the frequency of Smad4 gene mutant inactivation was high in solid tumor types, including breast carcinoma ([@b27-ol-0-0-11297]--[@b29-ol-0-0-11297]), which may partially explain the loss of Smad4 expression in the present study. Similar results have been discovered in the study of prostate carcinoma cell lines with different invasive and metastatic capacities: Smad2 was highly expressed in these cells, but the expression levels of p-Smad2 and Smad4 were different from each other, while a loss of expression was observed for each of them ([@b30-ol-0-0-11297]). Based on this, it was speculated that the progression of the malignant tumor types may be due to the interruption of the Smad activation process in the TGF-β signaling pathway.

In the present study, although neither p-Smad2 nor Smad4 were independent predictors, a substantial agreement in classification was observed between p-Smad2 and Smad4 expression. In addition, a Kaplan-Meier curve and Cox proportional hazards model revealed that p-Smad2/Smad4 co-positive patients had a longer OS and PFS time, in addition to a better prognosis, compared with p-Smad2/Smad4 co-negative patients. Based on the aforementioned results, it was speculated that the progression of these p-Smad2/Smad4 co-negative patients may have been due to the inability of Smad2 to phosphorylate, and at the same time the loss of Smad4 expression, which made Smad2 unable to form a heterologous complex with Smad4, and thus unable to form a transcription complex for the regulation of target gene transcription; as a result, the TGF-β/Smad pathway was disrupted, resulting in cell growth inhibition prevention and cell proliferation initiation ([@b31-ol-0-0-11297]). Another study revealed that the expression of the interstitial marker proteins vimentin and N-cadherin in breast carcinoma cells were increased following the inhibition of Smad2 expression, while the expression of the epithelial marker protein E-cadherin was decreased, suggesting the occurrence of EMT. It was through EMT that epithelial cells acquired an invasive ability, which promoted malignant tumor cell metastasis ([@b32-ol-0-0-11297]). In turn, the co-activation of p-Smad2 and Smad4 may serve a synergistic function in tumor suppression by transmitting TGF-β signaling in the 100 p-Smad2/Smad4 co-positive expression breast carcinoma cases, resulting in a longer survival time and better prognosis. In a similar study, although the effect of p-Smad2 and Smad4 co-expression or co-inactivation on prognosis was not observed, the OS time of patients with breast carcinoma which was p-Smad2-positive was significantly longer compared with that of p-Smad2-negative patients ([@b33-ol-0-0-11297]), which may have been due to the distinct specimen groups, the cut-offs used for the assessment or the antibodies used. Furthermore, the close correlation between p-Smad2 and Smad4 expression was also discovered in other types of cancer, including osteosarcoma; Smad4 expression was significantly associated with p-Smad2 expression, and they each co-regulated the expression of the cell cycle inhibitor p21/waf1 to inhibit tumor cell growth ([@b34-ol-0-0-11297]).

In conclusion, the results of the present study indicated that Smad4-positive patients had a better prognosis compared with Smad4-negative patients, although Smad4 expression could not be used as an independent predictor. Of note, at least in a part of breast ductal carcinomas, patients with a p-Smad2/Smad4 co-negative expression had a poor prognosis, as compared with p-Smad2/Smad4 co-positive patients. In addition, according to the results of the present study, p-Smad2 and Smad4 co-expression or co-inactivation may be seen as an independent predictor of prognosis in patients with invasive breast ductal carcinoma. Since, in most cases, the primary diagnosis of breast ductal carcinomas is based on histopathological sections, such breast cancer samples are therefore critical in guiding the clinical management of the disease, potentially helping to avoid improper or excessive treatment. Of course, it is also limited to detecting the expression of proteins in paraffin samples only by immunohistochemistry, and future research will attempt to confirm the results of the present study by analyzing Smad2, p-Smad2 and Smad4 mRNA and protein levels in fresh breast ductal carcinoma samples.
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![Representative immunohistochemical staining of Smad2, p-Smad2 and Smad4 in (A) and (B) two different breast ductal carcinoma specimens. The expression of Smad2, p-Smad2 and Smad4 were strong, negative and negative in (A) specimens, respectively. The expression of Smad2, p-Smad2 and Smad4 were strong, moderate and weak in (B) specimens, respectively. Smad2, SMAD family member 2; Smad4, SMAD family member 4; p-, phosphorylated.](ol-19-03-1789-g00){#f1-ol-0-0-11297}

![(A) Overall and (B) progression-free survival time of patients stratified according to Smad4 expression. Smad4, SMAD family member 4.](ol-19-03-1789-g01){#f2-ol-0-0-11297}

![(A) Overall and (B) progression-free survival time of patients stratified according to p-Smad2/Smad4 co-positive and co-negative expression. Smad4, SMAD family member 4; p-Smad2, phosphorylated SMAD family member 2.](ol-19-03-1789-g02){#f3-ol-0-0-11297}

###### 

Association of clinicopathological parameters with Smad2, p-Smad2 and Smad4 expression in 126 patients with breast ductal carcinoma.

                                Smad2                 p-Smad2              Smad4                                
  ----------------------- ----- ------- ---- -------- --------- ---- ----- -------- ------- ---- ----- -------- -----------------------------------------------------
  Age (years)                   60      66                      25   101                    21   105            
    \<48                  62    31      31   0.047    0.602     11   51    −0.052   0.564   10   52    −0.014   0.875
    ≥48                   64    29      35                      14   50                     11   53             
  Histological grade                                                                                            
    I                     17    8       9    −0.022   0.806     3    14    −0.048   0.595   2    15    −0.027   0.762
    II                    79    37      42                      15   64                     14   65             
    III                   30    15      15                      7    23                     5    25             
  Tumor size                                                                                                    
    T2                    99    51      48   0.149    0.095     19   80    −0.031   0.729   16   83    −0.026   0.773
    T3                    27    9       18                      6    21                     5    22             
  Lymph node metastasis                                                                                         
    N0                    42    21      21   0.023    0.801     12   30    0.130    0.146   10   32    0.104    0.247
    N1                    37    17      20                      6    31                     5    32             
    N2                    24    11      13                      3    21                     2    22             
    N3                    23    11      12                      4    19                     4    19             
  Distant metastasis                                                                                            
    M0                    118   57      61   0.053    0.557     24   94    0.048    0.594   20   98    0.029    0.746
    M1                    8     3       5                       1    7                      1    7              
  ER                                                                                                            
    Negative              92    43      49   −0.029   0.747     20   72    0.078    0.384   18   72    0.141    0.114
    Positive              34    17      17                      5    29                     3    33             
  PR                                                                                                            
    Negative              89    44      45   0.056    0.530     16   73    −0.072   0.420   14   75    −0.039   0.665
    Positive              37    16      21                      9    28                     7    30             
  HER2                                                                                                          
    Negative              94    46      48   0.045    0.615     15   79    −0.167   0.062   12   82    −0.179   0.044^[a](#tfn1-ol-0-0-11297){ref-type="table-fn"}^
    Positive              32    14      18                      10   22                     9    23             

P\<0.05. Smad, SMAD family member; p-, phosphorylated; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

###### 

Agreement between Smad4 and p-Smad2 expression.

                    p-Smad2                 
  ---------- ------ --------- ----- ------- -----------------------------------------------------
  Negative     21   20          1   0.841   0.001^[a](#tfn2-ol-0-0-11297){ref-type="table-fn"}^
  Positive   105      5       100           
  Total      126    25        101           

P\<0.05. Smad, SMAD family member; p-, phosphorylated.

###### 

Univariate analysis of clinicopathological parameters for overall and progression-free survival in 126 breast ductal carcinoma patients.

                                Overall survival time (months)   Progress-free survival time (months)                                         
  ----------------------- ----- -------------------------------- ----------------------------------------------------- ---------------------- -----------------------------------------------------
  Age (year)              126                                    0.502                                                                        0.982
    \<48                  62    1                                                                                      1                      
    ≥48                   64    1.270 (0.632--2.554)                                                                   0.994 (0.594--1.664)   
  Histological grade                                             0.093                                                                        0.130
    I                     17    1                                                                                      1                      
    II                    79    2.211 (0.515--9.492)                                                                   1.075 (0.475--2.430)   
    III                   30    4.164 (0.922--18.809)                                                                  1.881 (0.785--4.509)   
  Tumor size                                                     0.158                                                                        0.535
    T2                    99    1                                                                                      1                      
    T3                    27    1.742 (0.806--3.768)                                                                   1.216 (0.656--2.255)   
  Lymph node metastasis                                          0.964                                                                        0.702
    N0                    42    1                                                                                      1                      
    N1                    37    0.842 (0.339--2.093)                                                                   1.344 (0.710--2.543)   
    N2                    24    1.018 (0.394--2.626)                                                                   0.891 (0.411--1.932)   
    N3                    23    1.099 (0.406--2.971)                                                                   1.148 (0.530--2.489)   
  Distant metastasis                                             0.017^[a](#tfn3-ol-0-0-11297){ref-type="table-fn"}^                          0.010^[a](#tfn3-ol-0-0-11297){ref-type="table-fn"}^
    M0                    118   1                                                                                      1                      
    M1                    8     3.618 (1.262--10.369)                                                                  3.072 (1.313--7.185)   
  ER                                                             0.819                                                                        0.970
    Negative              92    1                                                                                      1                      
    Positive              34    1.094 (0.506--2.365)                                                                   0.989 (0.549--1.780)   
  PR                                                             0.384                                                                        0.766
    Negative              89    1                                                                                      1                      
    Positive              37    0.701 (0.315--1.560)                                                                   1.087 (0.628--1.882)   
  HER2                                                           0.098                                                                        0.563
    Negative              94    1                                                                                      1                      
    Positive              32    1.832 (0.895--3.747)                                                                   1.185 (0.666--2.109)   
  Smad2                                                          0.618                                                                        0.558
    Low                   60    1                                                                                      1                      
    High                  66    0.838 (0.419--1.617)                                                                   1.168 (0.695--1.965)   
  p-Smad2                                                        0.187                                                                        0.070
    Negative              25    1                                                                                      1                      
    Positive              101   0.595 (0.275--1.286)                                                                   0.581 (0.322--1.046)   
  Smad4                                                          0.051                                                                        0.040^[a](#tfn3-ol-0-0-11297){ref-type="table-fn"}^
    Negative              21    1                                                                                      1                      
    Positive              105   0.465 (0.215--1.005)                                                                   0.523 (0.282--0.971)   

P\<0.05. Smad, SMAD family member; p-, phosphorylated; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval.

###### 

Univariate analysis of clinicopathological parameters for overall and progression-free survival in patients with breast ductal carcinoma with a co-negative and co-positive p-Smad2/Smad4 expression.

                                      Overall survival time (months)   Progress-free survival time (months)                                         
  ----------------------------- ----- -------------------------------- ----------------------------------------------------- ---------------------- -----------------------------------------------------
  Age (year)                    120                                    0.516                                                                        0.999
    \<48                        59    1                                                                                      1                      
    ≥48                         61    0.793 (0.395--1.596)                                                                   1 (0.592--1.689)       
  Histological grade                                                   0.084                                                                        0.284
    I                           16    1                                                                                      1                      
    II                          76    2.163 (0.504--9.287)                                                                   1.047 (0.463--2.367)   
    III                         28    4.186 (0.927--18.904)                                                                  1.660 (0.682--4.038)   
  Tumor size                                                           0.158                                                                        0.447
    T2                          94    1                                                                                      1                      
    T3                          26    1.744 (0.806--3.772)                                                                   1.272 (0.684--2.367)   
  Lymph node metastasis                                                0.917                                                                        0.683
    N0                          40    1                                                                                      1                      
    N1                          36    0.806 (0.324--2.005)                                                                   1.215 (0.637--2.316)   
    N2                          23    0.998 (0.387--2.575)                                                                   0.781 (0.351--1.740)   
    N3                          21    1.176 (0.435--3.181)                                                                   1.243 (0.573--2.694)   
  Distant metastasis                                                   0.022^[a](#tfn4-ol-0-0-11297){ref-type="table-fn"}^                          0.012^[a](#tfn4-ol-0-0-11297){ref-type="table-fn"}^
    M0                          112   1                                                                                      1                      
    M1                          8     3.412 (1.190--9.777)                                                                   2.986 (1.274--6.998)   
  ER                                                                   0.770                                                                        0.919
    Negative                    89    1                                                                                      1                      
    Positive                    31    1.122 (0.519--2.425)                                                                   0.969 (0.529--1.774)   
  PR                                                                   0.463                                                                        0.675
    Negative                    85    1                                                                                      1                      
    Positive                    35    0.741 (0.333--1.650)                                                                   1.127 (0.643--1.976)   
  HER2                                                                 0.125                                                                        0.796
    Negative                    89    1                                                                                      1                      
    Positive                    31    1.751 (0.856--3.583)                                                                   1.081 (0.598--1.954)   
  Smad2                                                                0.750                                                                        0.543
    Low                         59    1                                                                                      1                      
    High                        61    0.893 (0.446--1.788)                                                                   1.178 (0.695--1.995)   
  p-Smad2 and Smad4                                                    0.047^[a](#tfn4-ol-0-0-11297){ref-type="table-fn"}^                          0.023^[a](#tfn4-ol-0-0-11297){ref-type="table-fn"}^
    p-Smad2/Smad4 co-negative   20    1                                                                                      1                      
    p-Smad2/Smad4 co-positive   100   0.458 (0.212--0.991)                                                                   0.486 (0.261--0.905)   

P\<0.05. Smad, SMAD family member; p-, phosphorylated; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval.

###### 

Multivariate analysis of clinicopathological parameters for overall and progression-free survival in patients with breast ductal carcinoma with a co-negative and co-positive p-Smad2/Smad4 expression.

  Variable                                  Comparison                                                HR      95% CI         P-value
  ----------------------------------------- --------------------------------------------------------- ------- -------------- -----------------------------------------------------
  Overall survival time (months)                                                                                             
  Distant metastasis                        M0 vs. M1                                                 3.383   1.178--9.713   0.024^[a](#tfn5-ol-0-0-11297){ref-type="table-fn"}^
  p-Smad2 and Smad4                         p-Smad2/Smad4 co-negative vs. p-Smad2/Smad4 co-positive   0.461   0.213--0.997   0.049^[a](#tfn5-ol-0-0-11297){ref-type="table-fn"}^
  Progression-free survival time (months)                                                                                    
  Distant metastasis                        M0 vs. M1                                                 2.840   1.209--6.668   0.017^[a](#tfn5-ol-0-0-11297){ref-type="table-fn"}^
  p-Smad2 and Smad4                         p-Smad2/Smad4 co-negative vs. p-Smad2/Smad4 co-positive   0.502   0.269--0.937   0.030^[a](#tfn5-ol-0-0-11297){ref-type="table-fn"}^

P\<0.05. Smad, SMAD family member; p-, phosphorylated; HR, hazard ratio; CI, confidence interval.
